Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289362 | 0.83 | AR (0.55) | ARTRPA1SLC22A12 | |
| SCHEMBL4903311 | 0.80 | AR (0.52) | ARSLC22A12 | |
| SCHEMBL3290604 | 0.80 | AR (0.52) | ARSLC22A12 | |
| SCHEMBL4898542 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL4898546 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL19976340 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL4905143 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL5120802 | 0.77 | AR (0.49) | ARSLC22A12 | |
| SCHEMBL24632242 | 0.76 | AR (0.49) | ARSLC22A12 | |
| SCHEMBL2973749 | 0.75 | AR (0.54) | ARTRPA1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2210603-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE ACCUMULATION OF AMYLOID- B PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1888512-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, BACE1 | AR 3599/4885TRPA1 3496/4885CNR2 4222/4885 |
| US-20090170907-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | AR 4/4885TRPA1 1654/4885CNR2 528/4885 |
| US-20060148893-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | AR 6/4885TRPA1 1911/4885CNR2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.